ArticlePediatric cardiology2026
Incidence and Risk Factors of Pulmonary Vein Stenosis After Orthotopic Heart Transplantation in Pediatric Patients.
Article in Pediatric cardiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Pulmonary vein stenosis after pediatric heart transplantation: incidence and risk factors.Frontiers in surgery · 2026Article
- Hiding in Plain Sight: Pulmonary Vein Stenosis Following Pediatric Heart Transplantation.Pediatric transplantation · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pulmonary vein stenosis (PVS) is a rare yet critical condition in children with a poor prognosis. The incidence and underlying risk factors of PVS following orthotopic heart transplantation (OHT) remain unclear. This study aimed to investigate the occurrence and predictors of PVS development post-OHT among pediatric recipients. This retrospective, single-center study was conducted at Cincinnati Children's Hospital Medical Center included patients who underwent OHT between 2014 and 2023. Demographics were compared between patients who developed PVS after OHT and those who did not. Cox regression analyses was used to identify predictors of PVS development. Among 114 patients (70 males, 61%) who underwent OHT at a median age of 11 years (IQR: 2-15), 12 were diagnosed with PVS (6 males, 50%) during a median follow-up of 29 months (IQR: 14-63). The median interval between OHT and diagnosis of PVS was 2 months (IQR: 1-8). All 12 PVS cases were associated with underlying congenital heart disease (12/69, 17.4%) including 2 patients with history of PVS at time of transplant. No patients with history of cardiomyopathy or myocarditis developed PVS. Among the 12 PVS patients, 3 (25%) had multivessel pulmonary vein disease and 4 patients (33%) died. Cox regression analysis, after excluding 2 patients with a prior history of PVS, identified age at OHT (Hazard ratio 0.86, p = 0.027) and partial or total anomalous pulmonary venous return (Hazard ratio 9.0, p = 0.002) as significant predictors of PVS development post-OHT. Prematurity, chronic lung disease, single ventricle physiology and donor-recipient size mismatch were not significantly associated with development of PVS post-OHT. The patients with PVS had significantly higher mortality compared to those without PVS (p = 0.025). This study highlights a low risk of PVS post-OHT in children with cardiomyopathy or myocarditis. PVS post-transplant is linked to congenital heart disease and early post-transplant period. Monitoring for PVS during the first year post-OHT is crucial, especially in children with congenital heart disease.
Indexed as
Identifiers
40056188What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.